In Brief This Week: NanoString; Genedata, Leco; Transgenomic; BioTime; Waters; ACMG, NBSTRN | GenomeWeb

NEW YORK (GenomeWeb News) – NanoString Technologies has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the firm to sell the test in the European Union and other countries that recognize the CE Mark. The test provides a subtype classification based on the fundamental biology of an individual's breast tumor and a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early-stage breast cancer who have been treated with hormonal therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.